文献速递眼底病与葡萄膜炎

碳酸酐酶抑制剂治疗葡萄膜炎性黄斑水肿:系统综述与Meta分析

CARBONIC ANHYDRASE INHIBITORS FOR MANAGING UVEITIC MACULAR EDEMA: A Systematic Review and Meta-Analysis.
PubMed 文献 · Retina · 2026-01-01

本系统综述与Meta分析纳入7项研究共187例参与者(236眼),均评估口服乙酰唑胺治疗葡萄膜炎性黄斑水肿。汇总视力改善比例为53%(95%CI:45%-60%),解剖学改善比例为55%(95%CI:32%-79%);与安慰剂相比,乙酰唑胺改善视力的可能性高14%,但未达统计学显著(风险差:0.14;95%CI:-0.04至0.31;P=0.12)。作者认为碳酸酐酶抑制剂尤其口服乙酰唑胺为葡萄膜炎性黄斑水肿提供了潜在替代选择,尤其适用于对类固醇难治或类固醇应答者。

要点

  • 共纳入7项研究、187例参与者(236眼),全部评估口服乙酰唑胺。
  • 汇总视力改善比例为53%(95%CI:45%-60%),解剖学改善比例为55%(95%CI:32%-79%)。
  • 乙酰唑胺较安慰剂改善视力的风险差为0.14(95%CI:-0.04至0.31;P=0.12),未达统计学显著。

核心结论

  • 碳酸酐酶抑制剂尤其口服乙酰唑胺为葡萄膜炎性黄斑水肿提供了潜在替代选择,尤其适用于对类固醇难治或类固醇应答的患者。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed/MEDLINE、Scopus、Google Scholar、Sage Journals、EBSCOhost和Cochrane Library,纳入评估碳酸酐酶抑制剂治疗葡萄膜炎性黄斑水肿的干预性与观察性研究。
  • 共纳入7项研究,合计187例参与者(236眼),全部研究口服乙酰唑胺。
  • 由两名评价者独立筛选和提取数据并评估研究质量与偏倚风险,采用随机效应模型进行比例Meta分析,研究注册于PROSPERO(CRD42024528004)。

主要发现

  • 汇总视力改善比例为53%(95%CI:45%-60%)。
  • 汇总解剖学改善比例为55%(95%CI:32%-79%)。
  • 与安慰剂相比,乙酰唑胺改善视力的风险差为0.14(95%CI:-0.04至0.31;P=0.12),未达统计学显著。

关键数值与推荐

  • 纳入研究需报告葡萄膜炎性黄斑水肿消退、复发、中心黄斑厚度变化、视力改善和不良事件等结局。

临床怎么用

  • 作者认为碳酸酐酶抑制剂尤其口服乙酰唑胺为葡萄膜炎性黄斑水肿提供了潜在替代选择,尤其适用于对类固醇难治或类固醇应答的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Uveitic macular edema (UME) is a leading cause of vision loss in uveitis. Although anti-inflammatory and immunosuppressive agents remain the mainstay of UME treatment, their use is often limited by corticosteroid-related side effects and the high cost of immunosuppressive therapies. This review aims to summarize the current evidence on carbonic anhydrase inhibitors as a potential treatment option for UME. METHODS: Electronic searches were conducted in PubMed/MEDLINE, Scopus, Google Scholar, Sage Journals, EBSCOhost, and the Cochrane Library for interventional and observational studies evaluating carbonic anhydrase inhibitors in UME. Eligible studies reported outcomes including UME resolution, recurrence, central macular thickness change, visual acuity improvement, and adverse effects. Two reviewers independently screened and extracted data, and assessed study quality and risk of bias. Meta-analysis of proportions was performed using a random-effects model. This study was registered in PROSPERO (CRD42024528004). RESULTS: Seven studies with a total of 187 participants (236 eyes) were included. All investigated oral acetazolamide. The pooled proportion of visual acuity improvement was 53% (95% CI: 45%-60%), and anatomical improvement was 55% (95% CI: 32%-79%). Acetazolamide showed a 14% higher likelihood of improving visual acuity compared with placebo, although not statistically significant (risk difference: 0.14; 95% CI: -0.04 to 0.31; P = 0.12). CONCLUSION: Carbonic anhydrase inhibitors, particularly oral acetazolamide, offer a potential alternative for managing UME, especially for patients who are refractory to steroids or are steroid-responders.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Excelinda T, Putera I, Ridwan AS, et al. CARBONIC ANHYDRASE INHIBITORS FOR MANAGING UVEITIC MACULAR EDEMA: A Systematic Review and Meta-Analysis. Retina. 2026. PMID: 40865073. doi:10.1097/IAE.0000000000004646

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。